文献速递肥胖与代谢综合征

整合遗传与肝脏转录组分析确定TRIB1AL为脂肪性肝病靶点

Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本研究通过GWAS荟萃分析(16 532例病例和1 240 188例对照)及504名魁北克肥胖生物库个体的肝脏RNA测序和基因分型,利用孟德尔随机化和共定位分析,确认了既往与MASLD相关基因,并发现AKNA、EPHA2、CHEK2、PCCB等新基因;长链非编码RNA TRIB1AL对MASLD有强正效应,且独立于TRIB1,低肝脏表达TRIB1AL与肝脏脂肪积累减少、血脂降低和动脉粥样硬化性心血管疾病风险降低相关。

要点

  • TRIB1AL lncRNA对MASLD有强正效应,且不依赖邻近蛋白编码基因TRIB1。
  • 低肝脏表达TRIB1AL与肝脏脂肪减少、血脂降低及ASCVD风险降低相关。
  • TRIB1 rare loss-of-function变异与肝脏脂肪积累或血浆甘油三酯无关。

核心结论

  • 肝脏表达的长链非编码RNA TRIB1AL是MASLD的潜在治疗靶点,沉默TRIB1AL可能降低肝脏脂肪、血脂和心血管风险。

研究设计与样本

  • GWAS荟萃分析纳入16 532例病例和1 240 188例对照;对504名魁北克肥胖生物库个体进行肝脏RNA测序和全基因组基因分型;另利用UK Biobank外显子组测序数据。

主要发现

  • 孟德尔随机化和共定位分析确认既往MASLD相关基因,并发现AKNA、EPHA2、CHEK2、PCCB等新基因。
  • TRIB1AL lncRNA对MASLD有强正效应,先导遗传变异与TRIB1表达无关。
  • UK Biobank中TRIB1 rare loss-of-function变异与肝脏脂肪积累或血浆甘油三酯水平无关。
  • 靶向和全表型MR显示低肝脏表达TRIB1AL与肝脏脂肪积累减少、血浆脂蛋白-脂质水平降低和ASCVD风险降低相关。

临床怎么用

  • TRIB1AL可作为MASLD及心血管代谢疾病的肝脏靶向治疗候选,尤其是通过沉默非编码基因组策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Genome-wide association studies (GWAS) have identified dozens of genetic loci linked with metabolic dysfunction-associated steatotic liver disease (MASLD). OBJECTIVE: To identify liver-expressed genes that may represent therapeutic candidates for MASLD. METHODS: We conducted a new GWAS meta-analysis including 16 532 cases and 1 240 188 controls. We also generated RNA sequencing data of liver samples and genome-wide genotyping of 504 individuals of the Quebec Obesity Biobank. RESULTS: Using mendelian randomization (MR) and genetic colocalization, we confirm the implication of genes previously linked with MASLD and identified novel ones including AKNA (AT-hook transcription factor), EPHA2 (EPH receptor A2), CHEK2 (encoding checkpoint kinase 2), and PCCB (propionyl-CoA carboxylase subunit β). More specifically, we found a strong and positive effect of long noncoding (lnc)RNA TRIB1AL on MASLD. The lead genetic variant was not linked with expression levels of the nearby protein-coding gene TRIB1 (Tribbles pseudokinase 1). In UK Biobank participants with whole-exome sequencing data available, rare loss-of-function variants in TRIB1 were not associated with liver fat accumulation or plasma triglyceride levels, suggesting that the lncRNA TRIB1AL may carry cardiometabolic effects independently of TRIB1. Targeted- and phenome-wide MR also identified lower liver-expressed TRIB1AL as being associated with reduced liver fat accumulation, lower plasma lipoprotein-lipid levels, and decreased atherosclerotic cardiovascular disease risk. CONCLUSION: These results open the door to liver-targeted therapeutics silencing of the noncoding genome for the prevention and treatment of MASLD and cardiometabolic diseases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gobeil É, Bourgault J, Gagnon E, et al. Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease. J Clin Endocrinol Metab. 2026. PMID: 41635218. doi:10.1210/clinem/dgag043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。